Navigation Links
Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010
Date:10/27/2010

NANJING, China, Oct. 27 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2010 on Thursday, November 11, 2010, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, November 11 at 9 p.m. Beijing/Hong Kong time).To access the conference call, please dial:United States toll-free:

+1.866.831.6291International:

+1.617.213.8860North China toll-free:

10.800.152.1490South China toll-free:

10.800.130.0399China toll free / Netcom:

10.800.852.1490Hong Kong:

+852.3002.1672Please ask to be connected to Q3 2010 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 18468376

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:

+1.888.286.8010 International:

+1.617.801.6888The passcode for replay participants is: 16680817.The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:Frank ZhaoChief Financial OfficerSimcere Pharmaceutical GroupTel: +86-25-8556-6666 ext 8818In Beijing:Ruirui JiangBrunswick Group Tel: +86-10-6566-2256In the United States:Kate TellierBrunswick GroupTel: +1-212-333-3810In Hong Kong:Joseph Lo Chi-LunBrunswick GroupTel: +852-3512-5000  
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group to Announce Second Quarter 2010 Financial Results on Thursday, August 12, 2010
2. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
3. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
4. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
5. Simceres Diosmectite API Passes EU-GMP Inspection
6. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
7. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
8. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
9. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
10. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
11. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 ... the growing legal cannabis industry is strongly contributing to ... provides comprehensive analysis and reporting for the cannabis industry, ... create more than a quarter million jobs for American ... $7.2 billion in 2016, and is projected to grow ...
(Date:3/22/2017)... March 22, 2017  As the world,s leading non-profit ... Society (LLS) has played a role in most therapies ... which are even helping patients with other cancers and ... significant investment in cutting-edge research – more than $1 ... grow with the record-breaking sum of $4.1 million raised ...
(Date:3/22/2017)... SANTA CLARA, Calif. , March 22, 2017 ... diagnostic cardiology  solutions segment, Frost & Sullivan recognizes ... Sullivan Company of the Year Award. GE Healthcare,s ... offer end-to-end cardiac solutions has allowed it to ... competitive cardiac monitoring products space. In addition to ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... HealthiPASS, Inc., announces ... creating a positive patient experience. , HealthiPASS has further enhanced its predictive ... by helping them understand their financial responsibility. “Our latest release focuses on ...
(Date:3/22/2017)... CA (PRWEB) , ... March 22, 2017 , ... Nearly ... should not undergo PSA (prostate-specific antigen) screening, the cancer screening continues to stir controversy. ... 2008 because it found that the risks outweighed the benefits. Now, news from ...
(Date:3/22/2017)... ... , ... The National Association for Business Resources (NABR) has recently ... in Wellness® companies for 2017. , American Specialty Health (ASH) was honored ... for its employees. ASH is one of only nine other San Diego companies being ...
(Date:3/22/2017)... ... March 22, 2017 , ... Winter ... reduces pigmentation to enhance surgical and nonsurgical procedures—Lytera 2.0 by SkinMedica. Lytera 2.0 ... the face, neck and décolletage in as little as 4 weeks. Skin pigmentation ...
(Date:3/20/2017)... ... ... The topic of healthcare in America has become one of the most ... is that they are still left without the health insurance coverage they need in ... that an unfortunate side-effect of this scenario is that hospital emergency rooms and urgent ...
Breaking Medicine News(10 mins):